MARKETSPERPSLIVE104
Cash
Portfolio
TrendingElectionsPoliticsCultureSportsCryptoCommoditiesClimateEconomicsMentions

Finance

Tech & Science
PredictLive104AccountSocial
Product
Kalshi ProPerpetual FuturesMarketsIncentive programInstitutionsAPI & developers
Company
AboutKalshi ResearchBlogCareersPolicy CenterBrand Kit
Help
Help CenterFAQFee scheduleTrading hoursRegulatoryTrust Center
© 2026 Kalshi Inc. · All rights reserved
PrivacyData Terms of ServiceTrading ProhibitionsFAQ for Finance Professionals
Trading on Kalshi involves risk and may not be appropriate for all. Members risk losing their cost to enter any transaction, including fees. You should carefully consider whether trading on Kalshi is appropriate for you in light of your investment experience and financial resources. Any trading decisions you make are solely your responsibility and at your own risk. Information is provided for convenience only on an "AS IS" basis. Past performance is not necessarily indicative of future results. Kalshi is subject to U.S. regulatory oversight by the CFTC.

Biotech

All markets
Public Companies Hub
Indices
Foreign Exchange
Interest Rates
Company metrics
Company news
Industries
Biotech
Ski Resorts
Advertising Spend
Match Ups
Companies
Markets
Biotech

FDA decision: Bepirovirsen by GlaxoSmithKline (this year)

Yes
1.08x
No
6.29x
$4,012 vol1 market
Biotech

FDA decision: Ivonescimab by Summit Therapeutics (this year)

Yes
1.01x
No
3.29x
$8,279 vol1 market
Biotech

FDA decision: Ifinatamab Deruxtecan by Daiichi Sankyo (this year)

Yes
1.14x
No
4.73x
$1,673 vol1 market
Biotech

FDA decision: Venglustat by Sanofi (this year)

Yes
1.16x
No
4.31x
$796 vol1 market
Biotech

FDA decision: Saroglitazar by Zydus Therapeutics (this year)

Yes
1.23x
No
3.52x
$1,117 vol1 market
Biotech

FDA decision: BBP-418 by Ml Bio Solutions Inc. (this year)

Yes
1.07x
No
7.85x
$831 vol1 market
Biotech

FDA decision: Anitocabtagene Autoleucel (anito-cel) by Gilead Sciences (this year)

Yes
1.08x
No
6.74x
$2,806 vol1 market